Vision genomics, LLC is a biotechnology-based company that focuses on research and development of therapeutics for age-related eye diseases. Our company undertakes an interdisciplinary approach using big data analysis to produce working solutions for age-related eye diseases.
Our primary disease of interest is Age-related macular degeneration (AMD). AMD is the leading cause of visual impairment and blindness in older adults and one of the most common causes of visual impairment worldwide. Vision Genomics, LLC is focused on operations and development of its AMD Medicine TM drug discovery with a personalized medicine platform. AMD Medicine TM was developed using the advanced genomic and transcriptomic analysis algorithms already successfully used in cancer research and precision medicine in oncology.
The AMD Medicine platform contains broad databases of gene expression, genetic and epigenetic data in ocular diseases as databases of drugs with known molecular targets and effects on gene expression in a variety of tissues and cell lines. It includes advanced parametric and machine learning algorithms that screen for drugs that minimize the difference between healthy and disease states while targeting signaling pathways that are pathologically activated or down regulated and accounting for pharmacogenomic effects.
For years the founding scientists have engaged in projects related to the understanding of the interplay of inter-cellular signaling pathways in age-related diseases and progeroid syndromes and have looked for interventions to modulate and delay the onset of the pathological processes resulting from and driving aging.
Age-related macular degeneration (AMD) was identified as one of the disease models , in which some of the interventions may be effective. To accelerate research scientists decided to form a company and engage with the country’s top ophthalmologists to find working personalized solutions for AMD.